Thiotriazoline 2.5% / 2 ml 10s solution for intramuscular and intravenous administration
- $26.10
Out Of Stock
Sku:
f9024f3eb048
Brand:
Halychpharm (Ukraine)
The instruction for medical use
of Tiotriazolin Torgovoye medicine a name
Tiotriazolin
Mezhdunarodnoye the unlicensed name
Is not present
the Dosage form
Solution for injections of 25 mg/ml
Structure
of 1 ml of solution contains
active agent - tiotriazolin, in terms of 100% substance, 25.0 mg
excipient - water for injections.
The description
Transparent, colourless or with slightly yellowish shade liquid
Pharmacotherapeutic group
Drugs for treatment of heart diseases
Other drugs for treatment of heart diseases
the Other cardiotonic
drugs ATX C01EB Code Pharmacological Pharmacokinetics Maximum Concentration Properties of a tiotriazolin in blood plasma is reached at intramuscular introduction – in 0.84 h, at intravenous – in 0.1 h. Linking with blood proteins does not exceed 10%. Tiotriazolin collects mainly in kidneys – 31%. In a significant amount it collects in a large intestine, heart, a spleen, least of all – in a small intestine and lungs (1-2%).
A pharmacodynamics
the Pharmacological effect of a tiotriazolin is caused by the antiischemic, membrane stabilizing, antioxidant and immunomodelling action.
Influence of drug is implemented due to strengthening of compensatory activation of anaerobic glycolysis and activation of processes of oxidation in a tricarbonic acid cycle with preservation of the ATP intracellular fund. Existence in structure of a molecule of a tiotriazolin of thiol of sulfur of which oxidation-reduction properties, and tertiary nitrogen which connects surplus of ions of hydrogen, causes activation of an antioxidant system are characteristic. Strong recovery properties of tiolny group cause reaction with active forms of oxygen and lipidic radicals. Reactivation of anti-radical enzymes – superoxide dismutases, catalases and glutathione peroxidases prevents initiation of active forms of oxygen.
Influence of a tiotriazolin leads to slowing down of processes of oxidation of lipids in ischemic sites of a myocardium, to reduction of sensitivity of a myocardium to catecholamines, prevention of progressive oppression of sokratitelny function of heart, stabilization and reduction according to a zone of necrosis and ischemia of a myocardium. Improvement of rheological properties of blood is carried out due to activation of a fibrinolytic system. Improvement of processes of metabolism of a myocardium, increase in its sokratitelny ability, contribution of normalization of a warm rhythm causes cardiotyre-tread effect of Tiotriazolin.
Tiotriazolin has properties of a gepatoprotektor: prevents destruction of hepatocytes, reduces extent of fat infiltration and spread of centrolobular necroses of a liver, promotes processes of reparative regeneration of hepatocytes, normalizes in them proteinaceous, carbohydrate, lipidic and pigmentary exchanges. Increases the speed of synthesis and biliation, normalizes its chemical composition.
Indications
as a part of complex therapy (as an additional tool):
- coronary heart disease (acute large or melkoochagovy myocardial infarction, angina of exertion and rest, a postinfarction cardiosclerosis)
- cardiac arrhythmias
- chronic hepatitis of various etiology (including alcoholic hepatitis)
- fibrosis and cirrhosis.
The route of administration and doses
the Adult in an acute myocardial infarction, chronic hepatitis with the significant activity of process of Tiotriazolin in the first 5 days enter intramusculary 2 ml 25 mg/ml of solution (on 50 mg) 2-3 times a day, or intravenously slowly with a speed of 2 ml/min. of 4 ml 25 mg/ml of solution (100 mg) once a day, or by drop infusion with a speed of 20-30 thaws a minute (2 ampoules of 25 mg/ml of solution dissolve 0.9% of solution of sodium of chloride in 150-250 ml). From the fifth to the twentieth day of therapy appoint Tiotriazolin in tablets (on 100 mg 3 times a day).
In an angina of exertion and rest and a postinfarction cardiosclerosis, chronic hepatitis of the minimum and moderate degree of activity of Tiotriazolin enter intramusculary 2 ml 25 mg/ml of solution 3 times a day. A course of treatment – 20-30 days. In cirrhosis a course of treatment – 60 days. Treatment there begin with intramuscular introduction 2 ml 25 mg/ml of solution (on 50 mg) 3 times a day for 5 days, and further continue treatment by tablets (on 100 mg 3 times a day).
Side effects
Seldom:
- an itching, a dermahemia, fever, skin rash (urtikarny, papular, punctulate, spotty)
- urticaria, a Quincke's disease
- dryness in a mouth, nausea, an abdominal distension, vomiting
Very seldom:
- an acute anaphylaxis
- the general weakness, dizziness, sonitus
- tachycardia, arterial hypertension
- short wind and suffocation.
Contraindications
– hypersensitivity to a tiotriazolin
– an acute renal failure
– pregnancy and the period of a lactation
– children's and teenage age up to 18 years.
Medicinal interactions
Tiotriazolin as cardiotyre-tread drug, it is possible to apply in a combination with basic means to therapy of coronary heart disease. As hepatoprotective means can be combined with purpose of traditional methods of treatment of hepatitis of the corresponding etiology.
The special
instructions Use at pregnancy and in the period of a lactation
the Use of drug during pregnancy or feeding by a breast was not studied.
Use in pediatrics
Experience of use of drug for children insufficient.
The feature of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms
does not influence.
Overdose
Symptoms: increase in urine of concentration of sodium and potassium.
Treatment: drug withdrawal, symptomatic treatment.
A form of release and packing
On 2 ml in ampoules or in ampoules with a ring of a break of red color or in ampoules with a break point.
On 10 ampoules put in blister strip packaging from a film polyvinylchloride.
On 1 blister strip packaging together with the instruction for medical use in the state and Russian languages and the scarificator ampoule put in a pack.
On 4 ml in ampoules with a capacity of 5 ml or in ampoules with a ring of a break of red color or in ampoules with a break point.
On 5 ampoules put in blister strip packaging from a film polyvinylchloride.
On the 2nd blister strip packagings together with the instruction for medical use in the state and Russian languages and the scarificator ampoule put in a pack.
To Store storage conditions in the place protected from light at a temperature not above 25 °C.
To store out of children's reach.
Not to apply a period of storage of 5 years after expiry date.
Prescription status
According to the prescription
the Arterium Corporation Producer, PJSC Galichpharm,
Ukraine, 79024, Lviv, Opryshkovskaya St., 6/8
the Owner of the registration certificate
of PJSC Galichpharm, Ukraine
the Address of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of products: Representative office of Arterium corporation in the Republic Kazakhstan050060, Almaty, Al-Farabi Avenue 97, 3 entrance, office 54 Ph. / fax: 8 (727) 315-82-09, 8 (727) 315-82-10, E-mail: Almaty@arterium.kz
of Tiotriazolin Torgovoye medicine a name
Tiotriazolin
Mezhdunarodnoye the unlicensed name
Is not present
the Dosage form
Solution for injections of 25 mg/ml
Structure
of 1 ml of solution contains
active agent - tiotriazolin, in terms of 100% substance, 25.0 mg
excipient - water for injections.
The description
Transparent, colourless or with slightly yellowish shade liquid
Pharmacotherapeutic group
Drugs for treatment of heart diseases
Other drugs for treatment of heart diseases
the Other cardiotonic
drugs ATX C01EB Code Pharmacological Pharmacokinetics Maximum Concentration Properties of a tiotriazolin in blood plasma is reached at intramuscular introduction – in 0.84 h, at intravenous – in 0.1 h. Linking with blood proteins does not exceed 10%. Tiotriazolin collects mainly in kidneys – 31%. In a significant amount it collects in a large intestine, heart, a spleen, least of all – in a small intestine and lungs (1-2%).
A pharmacodynamics
the Pharmacological effect of a tiotriazolin is caused by the antiischemic, membrane stabilizing, antioxidant and immunomodelling action.
Influence of drug is implemented due to strengthening of compensatory activation of anaerobic glycolysis and activation of processes of oxidation in a tricarbonic acid cycle with preservation of the ATP intracellular fund. Existence in structure of a molecule of a tiotriazolin of thiol of sulfur of which oxidation-reduction properties, and tertiary nitrogen which connects surplus of ions of hydrogen, causes activation of an antioxidant system are characteristic. Strong recovery properties of tiolny group cause reaction with active forms of oxygen and lipidic radicals. Reactivation of anti-radical enzymes – superoxide dismutases, catalases and glutathione peroxidases prevents initiation of active forms of oxygen.
Influence of a tiotriazolin leads to slowing down of processes of oxidation of lipids in ischemic sites of a myocardium, to reduction of sensitivity of a myocardium to catecholamines, prevention of progressive oppression of sokratitelny function of heart, stabilization and reduction according to a zone of necrosis and ischemia of a myocardium. Improvement of rheological properties of blood is carried out due to activation of a fibrinolytic system. Improvement of processes of metabolism of a myocardium, increase in its sokratitelny ability, contribution of normalization of a warm rhythm causes cardiotyre-tread effect of Tiotriazolin.
Tiotriazolin has properties of a gepatoprotektor: prevents destruction of hepatocytes, reduces extent of fat infiltration and spread of centrolobular necroses of a liver, promotes processes of reparative regeneration of hepatocytes, normalizes in them proteinaceous, carbohydrate, lipidic and pigmentary exchanges. Increases the speed of synthesis and biliation, normalizes its chemical composition.
Indications
as a part of complex therapy (as an additional tool):
- coronary heart disease (acute large or melkoochagovy myocardial infarction, angina of exertion and rest, a postinfarction cardiosclerosis)
- cardiac arrhythmias
- chronic hepatitis of various etiology (including alcoholic hepatitis)
- fibrosis and cirrhosis.
The route of administration and doses
the Adult in an acute myocardial infarction, chronic hepatitis with the significant activity of process of Tiotriazolin in the first 5 days enter intramusculary 2 ml 25 mg/ml of solution (on 50 mg) 2-3 times a day, or intravenously slowly with a speed of 2 ml/min. of 4 ml 25 mg/ml of solution (100 mg) once a day, or by drop infusion with a speed of 20-30 thaws a minute (2 ampoules of 25 mg/ml of solution dissolve 0.9% of solution of sodium of chloride in 150-250 ml). From the fifth to the twentieth day of therapy appoint Tiotriazolin in tablets (on 100 mg 3 times a day).
In an angina of exertion and rest and a postinfarction cardiosclerosis, chronic hepatitis of the minimum and moderate degree of activity of Tiotriazolin enter intramusculary 2 ml 25 mg/ml of solution 3 times a day. A course of treatment – 20-30 days. In cirrhosis a course of treatment – 60 days. Treatment there begin with intramuscular introduction 2 ml 25 mg/ml of solution (on 50 mg) 3 times a day for 5 days, and further continue treatment by tablets (on 100 mg 3 times a day).
Side effects
Seldom:
- an itching, a dermahemia, fever, skin rash (urtikarny, papular, punctulate, spotty)
- urticaria, a Quincke's disease
- dryness in a mouth, nausea, an abdominal distension, vomiting
Very seldom:
- an acute anaphylaxis
- the general weakness, dizziness, sonitus
- tachycardia, arterial hypertension
- short wind and suffocation.
Contraindications
– hypersensitivity to a tiotriazolin
– an acute renal failure
– pregnancy and the period of a lactation
– children's and teenage age up to 18 years.
Medicinal interactions
Tiotriazolin as cardiotyre-tread drug, it is possible to apply in a combination with basic means to therapy of coronary heart disease. As hepatoprotective means can be combined with purpose of traditional methods of treatment of hepatitis of the corresponding etiology.
The special
instructions Use at pregnancy and in the period of a lactation
the Use of drug during pregnancy or feeding by a breast was not studied.
Use in pediatrics
Experience of use of drug for children insufficient.
The feature of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms
does not influence.
Overdose
Symptoms: increase in urine of concentration of sodium and potassium.
Treatment: drug withdrawal, symptomatic treatment.
A form of release and packing
On 2 ml in ampoules or in ampoules with a ring of a break of red color or in ampoules with a break point.
On 10 ampoules put in blister strip packaging from a film polyvinylchloride.
On 1 blister strip packaging together with the instruction for medical use in the state and Russian languages and the scarificator ampoule put in a pack.
On 4 ml in ampoules with a capacity of 5 ml or in ampoules with a ring of a break of red color or in ampoules with a break point.
On 5 ampoules put in blister strip packaging from a film polyvinylchloride.
On the 2nd blister strip packagings together with the instruction for medical use in the state and Russian languages and the scarificator ampoule put in a pack.
To Store storage conditions in the place protected from light at a temperature not above 25 °C.
To store out of children's reach.
Not to apply a period of storage of 5 years after expiry date.
Prescription status
According to the prescription
the Arterium Corporation Producer, PJSC Galichpharm,
Ukraine, 79024, Lviv, Opryshkovskaya St., 6/8
the Owner of the registration certificate
of PJSC Galichpharm, Ukraine
the Address of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of products: Representative office of Arterium corporation in the Republic Kazakhstan050060, Almaty, Al-Farabi Avenue 97, 3 entrance, office 54 Ph. / fax: 8 (727) 315-82-09, 8 (727) 315-82-10, E-mail: Almaty@arterium.kz
Related Products
